c-Jun Overexpressing CAR-T Cells are Exhaustion-Resistant and Mediate Enhanced Antitumor Activity
Authors:
- Rachel Christina LynnRLRachel Christina Lynn
- David GennertDGDavid Gennert
- Elena SotilloESElena Sotillo
- Peng XuPXPeng Xu
- Zinaida GoodZGZinaida Good
- Hima AnbunathanHAHima Anbunathan
- Robert JonesRJRobert Jones
- Victor TieuVTVictor Tieu
- Jeffrey GranjaJGJeffrey Granja
- Charles DeBourcyCDCharles DeBourcy
- Robbie MajznerRMRobbie Majzner
Preprint
Abstract
SUMMARY: CAR T cells mediate antitumor effects in a small subset of cancer patients, but dysfunction due to T cell exhaustion is an important barrier to progress. To investigate the biology of exhaustion in human T cells expressing CAR receptors, we used a model system employing a tonically signaling CAR, which induces hallmarks of exhaustion described in other settings. Exhaustion was associated with a profound defect in IL-2 production alongside increased chromatin accessibility of AP-1 transcription factor motifs, and overexpression of numerous bZIP and IRF transcription factors that have been implicated in inhibitory activity. Here we demonstrate that engineering CAR T cells to overexpress c-Jun, a canonical AP-1 factor, enhanced expansion potential, increased functional capacity, diminished terminal differentiation and improved antitumor potency in numerous in vivo tumor models. We conclude that a functional deficiency in c-Jun mediates dysfunction in exhausted human T cells and that engineering CAR T cells to overexpress c-Jun renders them exhaustion-resistant, thereby addressing a major barrier to progress for this emerging class of therapeutics.Keywords
This publication has 51 references indexed in Scilit:
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaNature Medicine, 2018
- CAR T cell immunotherapy for human cancerScience, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyNature Medicine, 2017
- Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma KinaseMolecular Therapy, 2017
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejectionNature, 2017
- Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for SarcomasCancer Immunology Research, 2016
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptorsNature Medicine, 2015
- Cellular immunotherapy for pediatric solid tumorsCytotherapy, 2015